Merck & Co.

Merck stock after-hours at EUR 127.86: minus 0.41 percent

Merck & Co., Inc. (NYSE:MRK) Stock Price Target Raised at Scotiabank

Scotiabank has increased its price target for Merck & Co., Inc. (NYSE:MRK) from $155.00 to $180.00, reiterating a "sector outperform" rating and suggesting a 22.81% upside. This follows a trend of positive analyst sentiment, with the company holding a "Moderate Buy" consensus rating. Merck recently surpassed quarterly earnings and revenue expectations, although insider selling of nearly $30 million was noted over the past 90 days.

H.C. Wainwright raises Surrozen stock price target on Wnt pathway validation

H.C. Wainwright increased its price target for Surrozen Inc. (NASDAQ:SRZN) to $54 from $44, maintaining a Buy rating, after Merck's positive trial results validated the Wnt pathway. This validation is seen as beneficial for Surrozen's SZN-8141, which is slated to enter clinical trials for diabetic macular edema by year-end 2026. Despite a recent surge in stock price, InvestingPro analysis suggests the stock might be overvalued.

Merck shares may rise as key clinical trial results in oncology and other areas approach.

Bank of America maintains a 'buy' rating on Merck, anticipating a potential share re-rating due to upcoming clinical trial data in oncology and other pipeline areas. Key trials include Phase 3 results for SAC-TMT in lung cancer and data on intismeran, a personalized cancer vaccine developed with Moderna, with presentations expected at the European Society for Medical Oncology meeting. Despite a recent dip, Merck maintains a strong market cap and positive investor interest.

Moderna Stock Reached New 52-Week High: What's Happening?

Moderna (NASDAQ: MRNA) shares reached a new 52-week high of $198 due to anticipation surrounding upcoming clinical trial data for its experimental cancer treatment, intismeran autogene. The company's headline abstract on late-stage trial results for intismeran combined with Merck's Keytruda in melanoma patients has been accepted for the European Society for Medical Oncology Congress. Despite the rally and promising trial results, Bernstein SocGen Group maintained a "Market Perform" rating and a $45 price target, expressing skepticism about the stock's current valuation.

Bernstein reiterates Moderna stock rating on mRNA platform progress

Bernstein SocGen Group has reiterated a Market Perform rating and a $45.00 price target for Moderna Inc. (NASDAQ: MRNA) shares, despite the stock's significant surge over the past year. Analysts highlighted that Intismeran validates the broader mRNA therapeutics platform, with promising melanoma data expected. However, InvestingPro analysis suggests the stock is currently overvalued, leading to mixed sentiment among other analysts.

Moderna, Inc. Stock Analysis: Momentum Builds Amid Overbought Signals

Moderna, Inc. (MRNA) stock surged nearly 7% to a 52-week high of $194.82, displaying a strong bullish trend above all major moving averages. However, technical indicators like the daily RSI14 at 75.12 and price trading above the upper Bollinger Band suggest the stock is overbought and may be due for a pause or consolidation. While the overall trend remains bullish, short-term momentum on hourly charts shows signs of cooling, warranting disciplined positioning.

Moderna Stock Jumped 7% Thursday. The Real Test Comes at ESMO on October 24.

Moderna's stock surged 7% following investor optimism surrounding its personalized cancer vaccine, intismeran autogene, ahead of Phase 3 melanoma data presentation at ESMO on October 24. Despite the jump, the stock's current price of $195 significantly surpasses the average analyst target of $120. CEO Stéphane Bancel also reframed Moderna as an mRNA platform company, focusing on oncology and rare diseases, rather than solely a COVID-19 vaccine developer.

Moderna Stock Trends After Hours - Moderna (NASDAQ:MRNA), Merck & Co (NYSE:MRK)

Moderna (MRNA) shares are trending after hours following an announcement regarding its investigational mRNA-based individualized neoantigen therapy, intismeran autogene. The company will present three abstracts, including Phase 3 trial data evaluating intismeran with Merck & Co.'s (MRK) pembrolizumab, at the European Society for Medical Oncology Congress 2026. MRNA stock saw a significant jump of 6.98% during regular trading and edged higher in after-hours trading.

Biotech Stocks At 52-Week Highs - TKNO, MRNA, ATRC, ILMN

This article highlights several biotech stocks that reached 52-week highs on September 23, 2026, due to positive developments. Alpha Teknova Inc. (TKNO) saw growth from new products and increased revenue, while Moderna Inc. (MRNA) achieved highs after positive Phase 3 trial results for its melanoma treatment. AtriCure Inc. (ATRC) recorded strong revenue growth with its FDA-approved Afib treatments, and Illumina Inc. (ILMN) climbed due to significant revenue growth in genomics.

Moderna Inc Stock (MRNA) Moved Up by 5.16% on Sep 22: A Full Analysis

Moderna Inc. (MRNA) saw its stock rise by 5.16% due to positive market reaction to strong Phase 3 oncology trial data for its personalized cancer therapy and regulatory clearances for updated COVID-19 vaccines. Despite this recent upward momentum and positive analyst upgrades, the company faces ongoing challenges such as operational cash burn, net losses, and potential equity dilution from recent convertible note issuances. Investors are keenly awaiting detailed Phase 3 data, which will be a critical catalyst to justify the stock's current valuation amidst existing risks and some analyst downgrades.

Moderna Adds Another 5% and Is Up 500% in 2026. Can MRNA Stock Continue the Melt-Up?

Moderna's stock (MRNA) has surged over 500% in 2026, significantly outperforming its rival BioNTech, primarily due to positive top-line results from its personalized cancer therapy, intismeran, in a melanoma trial. The market is now keenly awaiting detailed Phase 3 data on October 24 at the ESMO Presidential Symposium, which carries significant binary risk for the stock's future trajectory. Investors are advised to consider the potential for either validation of the rally or a sharp compression of the stock's valuation based on the upcoming data.

Should You Buy Moderna Stock? Why Many Wall Street Analysts Say "No."

Moderna's stock has seen a significant surge due to positive clinical trial data for its mRNA-based cancer vaccine, co-developed with Merck. Despite this, many Wall Street analysts maintain a neutral or "hold" rating, with some downgrading the stock, believing the market has overreacted and that future trial results or immediate economic impacts are uncertain. Investors are advised to be cautious, with some experts suggesting waiting for the hype to subside before making long-term commitments, especially given recent share dilution through convertible debt.

Amgen Inc Stock (AMGN) Moved Up by 3.90% on Sep 22: Facts Behind the Movement

Amgen Inc. (AMGN) stock rose by 3.90% on September 22, driven by positive Phase 3 clinical trial results for dazodalibep in Sjögren's disease, which met its primary endpoint. The company's diverse late-stage pipeline, including its obesity candidate MariTide and oncology treatment IMDELLTRA, also contributed to investor confidence. Despite technical indicators showing a neutral to sell signal, analysts maintain an average price target of $389.14 with a "Hold" rating.

UBS reiterates Moderna stock rating ahead of melanoma data

UBS has reiterated a Neutral rating on Moderna Inc. (NASDAQ: MRNA) with a $150.00 price target ahead of anticipated Phase III melanoma trial results. The stock has seen significant movement, trading at $180.30, up over 20% in the past week, and near its 52-week high. The market is keenly awaiting the melanoma study results, expecting a hazard ratio of 0.65 or better, which could lead to a 10-20% stock increase, though InvestingPro analysis suggests the stock is currently overvalued.

Moderna Surges 9% as Phase 3 Melanoma Data Wins Presidential Symposium Slot; Merck and BioNTech Edge Higher

Moderna's shares surged 9% after its Phase 3 melanoma vaccine study for intismeran autogene was selected for a Presidential Symposium slot at the ESMO congress, signaling significant clinical potential. While no new efficacy data was released, the prestigious slot itself indicates the data is considered practice-changing. Merck, Moderna's partner, and BioNTech saw modest gains, suggesting the market views this as a re-rating specific to Moderna rather than a broad validation of mRNA oncology.

BioNTech Stock Recently Got Downgraded. But Is Wall Street Underestimating Its Cancer Pipeline?

BMO Capital Markets downgraded BioNTech (BNTX) from "outperform" to "market perform" and lowered its price target due to waning COVID-19 vaccine demand and a setback in its colorectal cancer vaccine trial. Despite these challenges and a revised revenue forecast, the article argues that BioNTech's extensive oncology pipeline, with over 25 Phase 2 and Phase 3 clinical studies, is being underestimated by Wall Street. The company also holds significant cash reserves, suggesting that investors can acquire a robust pipeline at a perceived value.

Moderna, Inc. (MRNA) To Present Phase 3 Melanoma Data at ESMO; Investor Webcast Set

Moderna (MRNA) is scheduled to present late-breaking Phase 3 data for its intismeran autogene in resected stage IIB–IV melanoma at the ESMO 2026 conference. The company will also host an investor webcast on October 24th to discuss these results. The acceptance of three abstracts, including a Presidential Symposium slot, highlights the perceived importance of this data, which could significantly impact Moderna's oncology pipeline and valuation.

Moderna (MRNA) Soars to Fresh High Ahead of Pipeline Updates This Week

Moderna (MRNA) shares surged to a three-year high in anticipation of upcoming pipeline updates, particularly at the Bernstein Insights: Healthcare Leaders and Disruptors 3rd Annual Healthcare Forum. The company is expected to present further Phase 3 trial data for its melanoma treatment candidate, intismeran autogene combined with Merck’s Keytruda, which previously showed positive results in recurrence-free and distant metastasis-free survival. This news highlights the potential of its mRNA-based cancer therapy in a large addressable market, increasing investor confidence despite a slight decrease in the number of hedge funds holding the stock.

Moderna stock hits 52-week high at 176.75 USD

Moderna's stock has reached a new 52-week high of $176.75 USD, trading at $176.21 USD with a market capitalization of $70.4 billion. This significant surge, reflecting a 510% one-year price total return and a 422% year-to-date increase, is attributed to advancements in its biotechnology sector, particularly its COVID-19 vaccine development. However, InvestingPro analysis advises caution due to high price volatility and expectations of unprofitability this year, suggesting the stock may be overvalued.

Moderna Stock Jumps. Its mRNA Cancer Vaccine Is Getting Ready for Its Next Big Test.